What is String Bio?
String Bio operates at the intersection of synthetic biology and industrial chemistry, focusing on the conversion of methane—a potent greenhouse gas—into versatile chemical building blocks. The company's proprietary platform addresses the urgent need for sustainable alternatives to traditional petrochemical feedstocks. By transforming organic waste and methane into monomers suitable for biodegradable plastics and high-performance medical polymers, String Bio is effectively decoupling industrial production from fossil fuel reliance. This approach not only mitigates environmental impact but also enhances supply chain resilience for manufacturers seeking to meet stringent ESG mandates. The company's market position is defined by its ability to scale complex biological processes into cost-effective, robust solutions that serve both the consumer goods and medical device sectors.
How much funding has String Bio raised?
String Bio has raised a total of $20M across 1 funding round:
Series B
$20M
Series B (2022): $20M, investors not publicly disclosed
Key Investors in String Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for String Bio?
With this major strategic investment, String Bio is poised to accelerate its commercialization roadmap and expand its production capacity. The capital will likely be deployed toward optimizing bioreactor efficiency and scaling the synthesis of specialized polymers for high-performance applications. As the company moves deeper into its growth phase, the focus will shift toward establishing long-term partnerships with global chemical conglomerates and medical device manufacturers. By proving the economic viability of its circular value chain at an enterprise scale, String Bio aims to set a new standard for sustainable manufacturing, effectively turning environmental liabilities into high-value industrial assets. Future milestones will likely involve the expansion of its feedstock processing capabilities and the diversification of its monomer portfolio to address broader market demands.
See full String Bio company page
